Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RIGL – Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc.
RIGL
$21.91
Name : Rigel Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $391,584,288.00
EPSttm : 2.09
finviz dynamic chart for RIGL
Rigel Pharmaceuticals, Inc.
$21.91
4.04%
$0.85

Float Short %

13.77

Margin Of Safety %

28

Put/Call OI Ratio

0.25

EPS Next Q Diff

-0.39

EPS Last/This Y

1.27

EPS This/Next Y

-0.27

Price

21.91

Target Price

29.49

Analyst Recom

2.6

Performance Q

17.04

Relative Volume

0.86

Beta

1.21

Ticker: RIGL




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-07RIGL18.860.210.001190
2025-07-08RIGL18.420.210.071196
2025-07-09RIGL19.050.200.001235
2025-07-10RIGL19.580.200.001246
2025-07-11RIGL18.90.200.201268
2025-07-14RIGL19.360.200.001304
2025-07-15RIGL18.930.200.251310
2025-07-16RIGL19.290.200.001313
2025-07-17RIGL18.850.204.861320
2025-07-18RIGL18.80.210.551331
2025-07-21RIGL19.650.190.20985
2025-07-22RIGL20.090.190.381086
2025-07-23RIGL21.070.190.001091
2025-07-24RIGL20.470.180.001119
2025-07-25RIGL20.160.180.961128
2025-07-28RIGL20.010.200.171172
2025-07-29RIGL19.860.203.111193
2025-07-30RIGL21.040.231.091222
2025-07-31RIGL21.050.260.041282
2025-08-01RIGL21.880.250.341301
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-07RIGL18.832441.732.92.26
2025-07-08RIGL18.422441.731.42.26
2025-07-09RIGL19.042441.736.12.26
2025-07-10RIGL19.602441.735.82.26
2025-07-11RIGL18.882441.732.62.26
2025-07-14RIGL19.352441.735.42.26
2025-07-15RIGL18.902441.731.32.26
2025-07-16RIGL19.272441.734.82.26
2025-07-17RIGL18.912441.731.72.26
2025-07-18RIGL18.842441.732.82.26
2025-07-21RIGL19.622441.737.02.26
2025-07-22RIGL20.052441.735.32.26
2025-07-23RIGL21.072441.737.42.26
2025-07-24RIGL20.432441.730.72.26
2025-07-25RIGL20.172441.732.32.26
2025-07-28RIGL19.942441.732.32.26
2025-07-29RIGL19.902441.733.02.26
2025-07-30RIGL21.012441.737.92.26
2025-07-31RIGL21.062441.733.52.26
2025-08-01RIGL21.912441.736.62.26
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-07RIGL-3.8219.8712.07
2025-07-08RIGL-3.8219.8712.07
2025-07-09RIGL-3.8219.8712.07
2025-07-10RIGL-3.8219.8712.07
2025-07-11RIGL-3.8219.8712.51
2025-07-14RIGL-3.8220.1712.51
2025-07-15RIGL-3.8220.1712.51
2025-07-16RIGL-3.8220.1712.51
2025-07-17RIGL-3.8220.1712.51
2025-07-18RIGL-3.8220.1712.51
2025-07-21RIGL-3.8216.4412.51
2025-07-22RIGL-3.8216.4412.51
2025-07-23RIGL-3.8216.4412.51
2025-07-24RIGL-3.8216.4412.51
2025-07-25RIGL-3.8216.4413.77
2025-07-28RIGL-3.8215.7313.77
2025-07-29RIGL-3.8215.7313.77
2025-07-30RIGL-3.8215.7313.77
2025-07-31RIGL-3.8215.7313.77
2025-08-01RIGL-3.8215.7313.77
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

0.63

Avg. EPS Est. Current Quarter

1.41

Avg. EPS Est. Next Quarter

0.24

Insider Transactions

-3.82

Institutional Transactions

15.73

Beta

1.21

Average Sales Estimate Current Quarter

64

Average Sales Estimate Next Quarter

50

Fair Value

28.15

Quality Score

95

Growth Score

51

Sentiment Score

77

Actual DrawDown %

60.2

Max Drawdown 5-Year %

-86.4

Target Price

29.49

P/E

10.57

Forward P/E

13.57

PEG

0.73

P/S

1.93

P/B

21.08

P/Free Cash Flow

11.01

EPS

2.07

Average EPS Est. Cur. Y​

2.26

EPS Next Y. (Est.)

1.98

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

18.31

Relative Volume

0.86

Return on Equity vs Sector %

176.5

Return on Equity vs Industry %

195.1

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

36.6
Rigel Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 162
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
stock quote shares RIGL – Rigel Pharmaceuticals, Inc. Stock Price stock today
news today RIGL – Rigel Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RIGL – Rigel Pharmaceuticals, Inc. yahoo finance google finance
stock history RIGL – Rigel Pharmaceuticals, Inc. invest stock market
stock prices RIGL premarket after hours
ticker RIGL fair value insiders trading